You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GM2 Gangliosidosis

Showing 1 - 25 of 7,724
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Infantile GM2 Gangliosidosis (Disorder) Trial in Kingston (TSHA-101)

Active, not recruiting
  • Infantile GM2 Gangliosidosis (Disorder)
  • TSHA-101
  • Kingston, Ontario, Canada
    Queen's University/Kingston Health Sciences Centre
Sep 12, 2022

GM2 Gangliosidosis, Niemann-Pick Disease, Type C Trial in Curitiba, Porto Alegre, Rio De Janeiro (AZ-3102 (Dose 1), Placebo,

Not yet recruiting
  • GM2 Gangliosidosis
  • Niemann-Pick Disease, Type C
  • AZ-3102 (Dose 1)
  • +2 more
  • Curitiba, Brazil
  • +2 more
Feb 24, 2023

GM1 and GM2 Gangliosidosis PROspective Neurological Disease

Recruiting
  • GM1 Gangliosidosis
  • +2 more
    • Oakland, California
    • +12 more
    Nov 16, 2022

    A Natural History Study of the Gangliosidoses

    Recruiting
    • Tay-Sachs Disease
    • +4 more
      • Minneapolis, Minnesota
        University of Minnesota - Pediatric Genetics and Metabolism
      Feb 28, 2022

      GM2 Gangliosidosis, Supportive Care Trial in Kashan, Mashhad, Tehran (Miglustat)

      Recruiting
      • GM2 Gangliosidosis
      • Supportive Care
      • Kashan, Isfahan, Iran, Islamic Republic of
      • +2 more
      Oct 23, 2022

      Lysosomal Diseases, Gangliosidosis, GM1 Trial run by the NHGRI (biological, drug, diagnostic test, other, procedure, behavioral)

      Recruiting
      • Lysosomal Diseases
      • +2 more
      • AAV9-GLB1
      • +20 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 19, 2023

      GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2 Trial in Worldwide (PBGM01)

      Recruiting
      • GM1 Gangliosidosis
      • +3 more
      • PBGM01
      • Oakland, California
      • +9 more
      Mar 10, 2022

      Infantile and Juvenile GM1 Gangliosidosis (GM1) Patients

      Recruiting
      • GM1 Gangliosidosis
        • Oakland, California
        • +5 more
        Feb 2, 2023

        Tay-Sachs Disease Sandhoff Disease Trial in Worldwide (venglustat GZ402671, )

        Active, not recruiting
        • Tay-Sachs Disease Sandhoff Disease
        • venglustat GZ402671
        • placebo
        • Los Angeles, California
        • +23 more
        Jan 31, 2022

        Gangliosidoses, GM1 Gangliosidosis, Morquio B Disease Trial in Hochheim

        Recruiting
        • Gangliosidoses
        • +8 more
          • Hochheim, HE, Germany
            SphinCS Lyso gemeinnützige UG (haftungsbeschränkt)
          Nov 5, 2020

          Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)

          Active, not recruiting
          • Hepato-splenomegaly
          • +3 more
            • Cairo, Egypt
            • +4 more
            May 12, 2021

            GM2 Gangliosidosis Trial in Boston

            Recruiting
            • GM2 Gangliosidosis
              • Boston, Massachusetts
                Massachusetts General Hospital
              Sep 8, 2020

              GM1 Gangliosidoses, GM2 Gangliosidoses, Tay-Sachs Disease Trial in Minneapolis (miglustat, Ketogenic Diet)

              Terminated
              Has Results
              • GM1 Gangliosidoses
              • +3 more
              • Minneapolis, Minnesota
                University of Minnesota
              Mar 18, 2021

              ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn

              Enrolling by invitation
              • Acid Sphingomyelinase Deficiency
              • +13 more
              • Confirmatory Testing
              • Bronx, New York
              • +9 more
              May 9, 2022

              Interviews and Video Capture in Patients With GM1 Gangliosidosis

              Recruiting
              • GM1 Gangliosidosis
              • Natural history
              • Plymouth, Massachusetts
                Casimir Trials
              Aug 23, 2021

              Glycosphingolipid and Glycoprotein Lysosomal Storage Disorders

              Recruiting
              • Neurological Regression
              • +3 more
                • Bethesda, Maryland
                  National Institutes of Health Clinical Center
                Jan 14, 2023

                GM1 Gangliosidosis Trial in Orange, Paris, Manchester (LYS-GM101)

                Recruiting
                • GM1 Gangliosidosis
                • LYS-GM101
                • Orange, California
                • +2 more
                Jun 30, 2021

                Brain Metastases, Radiotherapy Side Effect, Cognitive Impairment Trial in Guangzhou (Monosialotetrahexosyl ganglioside (GM1),

                Recruiting
                • Brain Metastases
                • +4 more
                • Monosialotetrahexosyl ganglioside (GM1)
                • Control
                • Guangzhou, Guangdong, China
                  Sun Yat-sen University Cancer Center
                Nov 3, 2021

                Tay-Sachs Disease, Sandhoff Disease Trial in Boston, Worcester (AXO-AAV-GM2 Starting Dose, AXO-AAV-GM2 Low Dose, AXO-AAV-GM2

                Recruiting
                • Tay-Sachs Disease
                • Sandhoff Disease
                • AXO-AAV-GM2 Starting Dose
                • +3 more
                • Boston, Massachusetts
                • +1 more
                Jan 26, 2021

                The Natural History of Metachromatic Leukodystrophy

                Recruiting
                • MLD
                • +26 more
                • Palliative Care
                • Hematopoetic Stem Cell Transplantation
                • Pittsburgh, Pennsylvania
                  The Program for the Study of Neurodevelopment in Rare Disorders,
                Nov 2, 2021

                Psoriasis Vulgaris, Fractional CO2 Laser Trial in Assiut (Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone

                Completed
                • Psoriasis Vulgaris
                • Fractional CO2 Laser
                • Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm
                • Fractional carbon dioxide (CO2) laser
                • Assiut, Egypt
                  Assiut University
                Aug 23, 2023

                ICU Acquired Weakness Trial (patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic

                Not yet recruiting
                • ICU Acquired Weakness
                • patients who will receive 2 gm protein/kg/day will be evaluated by ultrasound for diaphragmatic function and quadriceps muscle thickness
                • (no location specified)
                Sep 13, 2023

                DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)

                Recruiting
                • Diffuse Large B-Cell Lymphoma
                • Suzhou, Jiangsu, China
                  the First Affiliated Hospital of Soochow University
                Apr 10, 2023

                NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

                Not yet recruiting
                • Carcinoma, Non-Small-Cell Lung
                • Carcinoma Breast
                • Suzhou, China
                  Second Affiliated Hospital of Soochow University
                Oct 29, 2022

                HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor Trial in Seattle

                Active, not recruiting
                • HER2-positive Breast Cancer
                • +8 more
                • pNGVL3-hICD vaccine
                • +6 more
                • Seattle, Washington
                  Fred Hutchinson Cancer Research Center/University of Washington
                Nov 1, 2022